Dimethyl Fumarate

證據等級: L5

預測適應症: 10 個

Dimethyl Fumarate: From Relapsing-Remitting Multiple Sclerosis to Progressive Multiple Sclerosis

One-Sentence Summary

Dimethyl fumarate (DMF, brand name Tecfidera) is an oral immunomodulator with established approval in the EU and US for relapsing-remitting multiple sclerosis (RRMS), acting through antioxidant and anti-inflammatory pathways. The TxGNN model predicts it may be effective for Progressive Multiple Sclerosis, with 2 directly relevant clinical trials (including a completed Phase 2 RCT specifically in primary progressive MS) and 19 publications currently supporting this direction. While the key RCT did not meet its primary endpoint, the mechanistic rationale and accumulating real-world data make this a worthwhile candidate for further evaluation.

Quick Overview

Item	Content
Original Indication	Relapsing-Remitting Multiple Sclerosis (RRMS)
Predicted New Indication	Progressive Multiple Sclerosis
TxGNN Prediction Score	90.67%
Evidence Level	L2
Taiwan Market Status	Not Marketed
Number of Authorizations (Taiwan)	0
Recommended Decision	Proceed with Guardrails

Note: DMF (Tecfidera) holds EU approval (EMA, January 2014) and US FDA approval (2013) for RRMS. It is not currently registered in Taiwan.

Why is This Prediction Reasonable?

Detailed mechanism of action data is not available in the current Evidence Pack. Based on published literature and the repurposing rationale, DMF activates the Nrf2 (Nuclear factor erythroid 2–related factor 2) transcription pathway, enhancing cellular antioxidant defenses, while simultaneously downregulating Th1/Th17 pro-inflammatory cytokine production and upregulating the anti-inflammatory Th2 response. This dual immunomodulatory and neuroprotective profile is what drives its established efficacy in RRMS.

Progressive MS — both primary progressive (PPMS) and secondary progressive (SPMS) — differs fundamentally from RRMS in that neurodegeneration and oxidative stress, rather than acute demyelinating attacks, become the dominant drivers of disability accumulation. This pathological shift is precisely where DMF’s Nrf2-mediated neuroprotection may offer unique value: by reducing reactive oxygen species burden and shielding oligodendrocytes from damage, DMF targets mechanisms that are largely untouched by conventional anti-inflammatory DMTs. Most existing immunotherapies have minimal impact once the progressive phase has begun, creating significant unmet need.

The TxGNN prediction is directly supported by a completed Phase 2 RCT (NCT02959658) that specifically enrolled PPMS patients, with results published in Neurology: Neuroimmunology & Neuroinflammation (PMID 34429340) and an open-label extension (PMID 36586351). Although the primary endpoint — reduction in CSF neurofilament light chain (NFL) concentration — was not met in the placebo-controlled phase, open-label extension data and a real-world cohort study in progressive MS (PMID 33996142) suggest residual signals worth pursuing. A terminated Phase 3 trial in SPMS (NCT02430532) further demonstrates that this hypothesis has previously attracted serious clinical investment from Biogen.

Clinical Trial Evidence

Trial Number	Phase	Status	Enrollment	Key Findings
NCT02959658	Phase 2	Completed	54	Core RCT: randomized, placebo-controlled trial of DMF in primary progressive MS (PPMS); 48-week treatment; primary endpoint (CSF NFL reduction) not met; open-label extension data published (PMID 36586351)
NCT03092544	Phase 4	Unknown	57	Investigates indirect neuroprotective mechanism of DMF (Tecfidera) in both RRMS and progressive MS patients, including gut microbiome–immune axis analysis; directly evaluates DMF in progressive phenotype
NCT02430532	Phase 3	Terminated	58	Randomized, double-blind, placebo-controlled study of DMF (BG00012) in secondary progressive MS (SPMS); primary objective was slowing disability accumulation independent of relapses; terminated early after limited enrollment
NCT02683863	Phase 4	Completed	20	Open-label PK study exploring CNS penetration of DMF/MMF (its active metabolite) in SPMS via matched blood/CSF sampling; relevant to whether DMF reaches the progressive disease compartment
NCT07138833	Phase 4	Not Yet Recruiting	50	Multicenter open-label trial of DMF enteric-coated capsules in relapsing MS including active SPMS; expected start 2025, completion 2028
NCT03535298	Phase 4	Active, Not Recruiting	800	DELIVER-MS: pragmatic RCT comparing early intensive vs escalation DMT strategies in RRMS; DMF is one of available agents; informs long-term disability prevention strategy
NCT03500328	N/A	Active, Not Recruiting	900	TREAT-MS: early aggressive vs escalation therapy in MS; DMF is an available comparator; addresses whether preventing progressive conversion can be achieved via early treatment
NCT03193866	N/A	Completed	3,526	COMBAT-MS: large prospective observational cohort comparing rituximab vs all approved DMTs including DMF in RRMS; n=3,526; real-world comparative effectiveness data

Literature Evidence

PMID	Year	Type	Journal	Key Findings
34429340	2021	RCT	Neurology: Neuroimmunology & Neuroinflammation	Phase 2 RCT of DMF vs placebo in PPMS (n=54, 48 weeks); primary endpoint (CSF neurofilament light chain reduction) not met; key direct evidence for DMF in progressive MS
36586351	2023	Open-label Extension	Multiple Sclerosis and Related Disorders	Open-label extension of the PPMS RCT; reports longer-term outcomes of DMF in PPMS beyond the controlled phase
33996142	2021	Real-world Cohort	MS Journal – Experimental, Translational and Clinical	Real-world safety and effectiveness analysis of DMF in progressive MS populations; limited prior published data in this group
38174776	2024	Network Meta-analysis	Cochrane Database of Systematic Reviews	Updated Cochrane network meta-analysis of immunomodulators and immunosuppressants for RRMS; contextualizes DMF’s comparative efficacy across the DMT landscape
29686116	2018	Clinical Practice Guideline	Neurology	AAN guideline recommendations for DMTs in MS; provides authoritative positioning of DMF across MS phenotypes
25900414	2015	Systematic Review	Cochrane Database of Systematic Reviews	Cochrane review of DMF for MS; synthesizes DEFINE and CONFIRM Phase 3 RCT data establishing DMF’s RRMS evidence base
27433310	2016	Narrative Review	Therapeutic Advances in Chronic Disease	Review of DMF after >190,000 patients treated globally; covers real-world experience, neuroprotective mechanisms, and biomarker data relevant to progressive disease
34465252	2022	Long-term Extension	Multiple Sclerosis	ENDORSE study: up to 13 years of DMF follow-up in RRMS; confirms sustained favorable benefit–risk profile informing safety expectations in a new indication
32808554	2022	Safety Cohort	Multiple Sclerosis	Nine PML cases in DMF-treated MS patients reported; estimated PML incidence 0.02 per 1,000 patients; risk concentrated in those with severe or prolonged lymphopenia
33091427	2021	Systematic Review	Pharmacology & Therapeutics	Comprehensive review of DMF-induced lymphopenia mechanisms and PML risk; critical reference for monitoring protocol design in a progressive MS population

Safety Considerations

Please refer to the SmPC for safety information.

Key safety signal from evidence review: Multiple publications in the evidence set (PMIDs 32808554, 36387034, 38321317) document an association between DMF treatment and Progressive Multifocal Leukoencephalopathy (PML), a rare but potentially fatal opportunistic brain infection caused by JC virus. The estimated incidence is approximately 0.02 per 1,000 patients, with risk concentrated in those with severe or prolonged lymphopenia (grade 3, <0.5 × 10⁹/L). Any repurposing protocol for progressive MS must include regular lymphocyte monitoring and a defined threshold for treatment interruption.

Conclusion and Next Steps

Decision: Proceed with Guardrails

Rationale: A completed Phase 2 RCT (NCT02959658) directly tested DMF in primary progressive MS and real-world cohort data for progressive MS are available — establishing an L2 evidence level and justifying continued investigation. However, the primary endpoint was not met and a Phase 3 SPMS trial was terminated early, meaning the efficacy signal requires targeted characterization (particularly by disease subtype and inflammatory activity) before broad adoption.

To proceed, the following is needed:

Retrieve full DMF SmPC (EU) to complete safety profile: warnings, contraindications, and special population guidance
Obtain DMF mechanism of action data from DrugBank (Nrf2/NF-κB pathway specifics and oligodendrocyte protection evidence)
Define the target progressive MS population precisely — active SPMS (with ongoing relapses, where anti-inflammatory effects remain relevant) is likely more tractable than inactive PPMS
Design a lymphocyte monitoring protocol with clear discontinuation thresholds to manage PML risk
Conduct subgroup analysis of published PPMS RCT data (NCT02959658) to identify potential responder characteristics (e.g., age, disability level, baseline NFL)
Monitor outcome of NCT07138833 (active SPMS arm) as emerging prospective evidence
Disclaimer

This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.